Head-to-head · free
PDS Biotechnology Corporation vs Rapport Therapeutics
PDSB vs RAPP — return on capital, cash generation, margins and balance sheet side by side.
PDSB
3 / 4
measures where PDSB leads
RAPP
1 / 4
measures where RAPP leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | PDSB · FY2025 | RAPP · FY2025 |
|---|---|---|
| Revenue | — | — |
| Net income | (8.5M) | (111.5M) |
| Revenue growth (yearly, multi-year) | — | — |
| Free cash flow | (27.8M) | (88.1M) |
| Free cash flow margin | — | — |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | -244.2% | -28.2% |
| Gross margin | — | — |
| Operating margin | — | — |
| Net debt / EBITDA | 0.31x | 0.42x |
Figures are as reported by each company; latest fiscal year shown.
Where PDS Biotechnology Corporation's cash went (FY2025)
- Capital spending
- $0
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Rapport Therapeutics's cash went (FY2025)
- Capital spending
- $616000
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free